Trial Profile
An open-label, single-dose and single- plus multiple-dose study to assess the pharmacokinetic profile of FLUTIFORM pMDI 50/5 μg (100/10 μg total dose), 125/5 μg (250/10 μg total dose), and 250/10 μg (500/20 μg total dose) in healthy Chinese subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2018
Price :
$35
*
At a glance
- Drugs Formoterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Mundipharma (China) Pharmaceutical
- 01 Nov 2018 New trial record